DUX4 and facioscapulohumeral muscular dystrophy: In summary, the present study provides substantial evidence that long-term systemic vivoPMO-PACS4 treatment in a mouse model of FSHD, with established disease, efficiently stabilizes the pathology progression through suppressing the expression of DUX4 and its downstream targets.